Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12477-12488

  Ahmadzadehfar, Hojjat ^a   Eppard, Elisabeth ^a   Kürpig, Stefan ^a   Fimmers, Rolf ^b   Yordanova, Anna ^a   Schlenkhoff, Carl Diedrich ^a   Gärtner, Florian ^a   Rogenhofer, Sebastian ^a   Essler, Markus ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

177Lu; Prostate cancer; PSA; PSMA; Radioligand therapy

Indexed keywords

ANTINEOPLASTIC AGENT; LUTETIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN DFKZ 617 LU 177; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; 177LU-DKFZ-617; 177LU-PSMA-617; DIPEPTIDE; LUTETIUM; ORGANOMETALLIC COMPOUND; PEPTIDE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS;

ADULT; AGED; ANEMIA; ARTICLE; BONE PAIN; CASTRATION RESISTANT PROSTATE CANCER; DISTANT METASTASIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPOGEUSIA; KIDNEY DISEASE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA; CHEMISTRY; DIAGNOSTIC IMAGING; MALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUTETIUM; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PEPTIDES; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84962905957     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7245     Document Type: Article

References (21)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer Journal international du cancer. 2015; 136:E359-386.
2. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60:277-300.
3. Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M and Li Y. Global analysis of differentially expressed genes in androgen-independent prostate cancer. Prostate cancer and prostatic diseases. 2007; 10:167-174.
4. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S and Montironi R. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. Journal of biological regulators and homeostatic agents. 2014; 28:555-563.
5. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, Kopka K and Haberkorn U. [Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2015; 42:987-988.
6. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL and Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer research. 2009; 69:6932-6940.
7. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, Gartner F, Rogenhofer S, Schafers M and Essler M. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI research. 2015; 5:114.
8. Zajic T and Moser E. [Procedure guidelines for dynamic renal scintigraphy]. Nuklearmedizin Nuclear medicine. 2004; 43:177-180.
9. Bubeck B, Brandau W, Weber E, Pomer S, Georgi P and zum Winkel K. Renal function studies using 99mTc-MAG3: pharmacokinetics and slope clearance determination. Contributions to nephrology. 1990; 79:72-73.
10. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012; 367:1187-1197.
11. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2015; 16:152-160.
12. Kist JW, de Keizer B, Stokkel MP, Hoekstra OS and Vogel WV. Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study. BMC cancer. 2014; 14:405.
13. Sainz-Esteban A, Prasad V, Schuchardt C, Zachert C, Carril JM and Baum RP. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. European journal of nuclear medicine and molecular imaging. 2012; 39:501-511.
14. Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, Afshar-Oromieh A, Debus J, Haberkorn U and Giesel FL. Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European journal of nuclear medicine and molecular imaging. 2016. 43:34-41.
15. Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA, Eckelman WC and Babich JW. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. Journal of medicinal chemistry. 2009; 52:347-357.
16. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW and Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. European journal of nuclear medicine and molecular imaging. 2014; 41:1280-1292.
17. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England journal of medicine. 2013; 369:213-223.
18. Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germa JR, O'Bryan-Tear CG, Haider T and Hoskin P. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. European urology. 2013; 63:189-197.
19. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH and Nanus DM. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research. 2013; 19:5182-5191.
20. Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E and Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. European journal of nuclear medicine and molecular imaging. 2015; 42:1976-1983.
21. Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P and Boning G. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2016; 43:42-51.